Use of a claims database to characterize and estimate the incidence rate for Castleman disease

References

• Castleman B, Towne VW. Case records of the Massachusetts General Hospital; weekly clinicopathological exercises; founded by Richard C. Cabot. N Engl J Med 1954;251:396–400.
   PubMedGoogle Scholar
• Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005;106:2627–2632.
   PubMed Web of Science ®Google Scholar
• Casper C. The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care. Br J Haematol 2005;129:3–17.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A. Castleman disease. Cancer Treat Res 2008;142: 293–330.
   PubMedGoogle Scholar
• van Rhee F, Stone K, Szmania S, et al. Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy. Clin Adv Hematol Oncol 2010;8:486–498.
   PubMedGoogle Scholar
• Dispenzieri A, Armitage JO, Loe MJ, et al. The clinical spectrum of Castleman's disease. Am J Hematol 2012;87:997–1002.
   PubMed Web of Science ®Google Scholar
• Dong Y, Na J, Lv J, et al. Clinical and laboratory characterization of a large cohort of patients with Castleman disease retrospectively collected from a single center. Leuk Lymphoma 2009;50:1308–1317.
   PubMed Web of Science ®Google Scholar
• van Rhee F, Fayad L, Voorhees P, et al. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. J Clin Oncol 2010;28:3701–3708.
   PubMed Web of Science ®Google Scholar
• Sarrot-Reynauld F. Castleman's disease. Orphanet encyclopedia [Internet]. August 2001. Available from: www.orpha.net/data/patho/GB/uk-castleman.pdf
   Google Scholar
• Talat N, Schulte KM. Castleman's disease: systematic analysis of 416 patients from the literature. Oncologist 2011;16:1316–1324.
   PubMed Web of Science ®Google Scholar
• Herrada J, Cabanillas F, Rice L, et al. The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med 1998;128:657–662.
   PubMed Web of Science ®Google Scholar
• Yuan XG, Chen FF, Zhu YM, et al. High prevalence of hepatitis B virus infection in HIV-negative Castleman's disease. Ann Hematol 2012;91:857–861.
   PubMed Web of Science ®Google Scholar
• Waterston A, Bower M. Fifty years of multicentric Castleman's disease. Acta Oncol 2004;43:698–704.
   PubMed Web of Science ®Google Scholar
• Wong R, Casper C, Munshi N, et al. A multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with multicentric Castleman's disease. Poster presented at the American Society for Hematology Annual Meeting and Exposition, 9 December 2013, New Orleans, LA.
   Google Scholar
• El-Osta HE, Kurzrock R. Castleman's disease: from basic mechanisms to molecular therapeutics. Oncologist 2011;16:497–511.
   PubMed Web of Science ®Google Scholar
• Bowne WB, Lewis JJ, Filippa DA, et al. The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature. Cancer 1999;85:706–717.
   PubMed Web of Science ®Google Scholar
• Chronowski GM, Ha CS, Wilder RB, et al. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer 2001;92:670–676.
   PubMed Web of Science ®Google Scholar
• Frizzera G, Peterson BA, Bayrd ED, et al. A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol 1985;3:1202–1216.
   PubMed Web of Science ®Google Scholar
• Weisenburger DD, Nathwani BN, Winberg CD, et al. Multicentric angiofollicular lymph node hyperplasia:a clinicopathologic study of 16 cases. Hum Pathol 1985;16:162–172.
   PubMed Web of Science ®Google Scholar
• Oksenhendler E, Duarte M, Soulier J, et al. Multicentric Castleman's disease in HIV infection: a clinical and pathological study of 20 patients. AIDS 1996;10:61–67.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Gertz MA. Treatment of Castleman's disease. Curr Treat Options Oncol 2005;6:255–266.
   PubMedGoogle Scholar
• Shannon E, Noveck R, Sandoval F, et al. Thalidomide suppressed interleukin-6 but not tumor necrosis factor-alpha in volunteers with experimental endotoxemia. Transl Res 2007;150:275–280.
   PubMed Web of Science ®Google Scholar
• Starkey CR, Joste NE, Lee FC. Near-total resolution of multicentric Castleman disease by prolonged treatment with thalidomide. Am J Hematol 2006;81:303–304.
   PubMed Web of Science ®Google Scholar
• Miltenyi Z, Toth J, Gonda A, et al. Successful immunomodulatory therapy in Castleman disease with paraneoplastic pemphigus vulgaris. Pathol Oncol Res 2009;15:375–381.
   PubMed Web of Science ®Google Scholar
• Beck JT, Hsu SM, Wijdenes J, et al. Brief report:alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med 1994;330:602–605.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Sasai M, Shima Y, et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 2000;95:56–61.
   PubMed Web of Science ®Google Scholar
• Kishimoto T. IL-6: from laboratory to bedside. Clin Rev Allergy Immunol 2005;28:177–186.
   PubMed Web of Science ®Google Scholar
• Ahmed B, Tschen JA, Cohen PR, et al. Cutaneous Castleman's disease responds to anti interleukin-6 treatment. Mol Cancer Ther 2007;6:2386–2390.
   PubMed Web of Science ®Google Scholar
• Estephan FF, Elghetany MT, Berry M, et al. Complete remission with anti-CD20 therapy for unicentric, non-HIV-associated, hyaline-vascular type, Castleman's disease. Cancer Invest 2005;23:191.
   PubMed Web of Science ®Google Scholar
• Ocio EM, Sanchez-Guijo FM, Diez-Campelo M, et al. Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena. Am J Hematol 2005;78: 302–305.
   PubMed Web of Science ®Google Scholar
• Hess G, Wagner V, Kreft A, et al. Effects of bortezomib on pro-inflammatory cytokine levels and transfusion dependency in a patient with multicentric Castleman disease. Br J Haematol 2006;134:544–545.
   PubMed Web of Science ®Google Scholar
• Sobas MA, Alonso Vence N, Diaz Arias J, et al. Efficacy of bortezomib in refractory form of multicentric Castleman disease associated to poems syndrome (MCD-POEMS variant). Ann Hematol 2010;89:217–219.
   PubMed Web of Science ®Google Scholar
• El-Osta H, Janku F, Kurzrock R. Successful treatment of Castleman's disease with interleukin-1 receptor antagonist (Anakinra). Mol Cancer Ther 2010;9:1485–1488.
   PubMed Web of Science ®Google Scholar
• Galeotti C, Tran TA, Franchi-Abella S, et al. IL-1RA agonist (anakinra) in the treatment of multifocal Castleman disease: case report. J Pediatr Hematol Oncol 2008;30:920–924.
   PubMed Web of Science ®Google Scholar
• Easterbrook PJ, Berlin JA, Gopalan R, et al. Publication bias in clinical research. Lancet 1991;337:867–872.
   PubMed Web of Science ®Google Scholar
• Orphanet Report Series. Prevalence of rare diseases: bibliographic data. November 2012. Number 1. Available from: www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_alphabetical_list.pdf
   Google Scholar
• Moore DF, Preti A, Tran SM. Prognostic implications following an indeterminate diagnostic work-up of lymphoma. Blood 1996;88(Suppl. 1): Abstract 229.
   Google Scholar
• Saeed-Abdul-Rahman I, Al-Amri AM. Castleman disease. Korean J Hematol 2012;47:163–177.
   PubMedGoogle Scholar
• Shin DY, Jeon YK, Hong YS, et al. Clinical dissection of multicentric Castleman disease. Leuk Lymphoma 2011;52:1517–1522.
   PubMed Web of Science ®Google Scholar
• Hennekens CH, Buring JE. Epidemiology in medicine. New York, NY: Little, Brown and Company; 1987. pp 64–66.
   Google Scholar
• Powles T, Stebbing J, Bazeos A, et al. The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman's disease. Ann Oncol 2009;20:775–779.
   PubMed Web of Science ®Google Scholar
• Hirt R, Krause U, Knipping S. [Castleman's disease: a rare differential diagnosis for Heerfordt's syndrome]. HNO 2012;60:1123–1126.
   PubMed Web of Science ®Google Scholar
• Awano N, Inomata M, Kondoh K, et al. Mixed-type multicentric Castleman's disease developing during a 17-year follow-up of sarcoidosis. Intern Med 2012;51:3061–3066.
   PubMed Web of Science ®Google Scholar
• Gurbuzler L, Ceylan A, Yilmaz M, et al. Castleman's disease of the parotid gland: a case report. Kaohsiung J Med Sci 2010;26:444–447.
   PubMed Web of Science ®Google Scholar